Neuroendocrine Impairments in PCOS: Pathogenesis and Therapeutic Interventions
Main Article Content
Abstract
Anovulatory infertility is primarily caused by the endocrine complication known as polycystic ovarian syndrome (PCOS). PCOS, which is characterized by hyperandrogenism, irregular periods, and polycystic ovaries, which is a multifaceted condition that is unlikely to have a single common cause. The brain is becoming a key candidate in both the ontogeny and pathophysiology of PCOS, despite the fact that it is still typically thought of as an ovarian disease. Impaired gonadal steroid hormone negative feedback to the GnRH neuronal network in the brain that controls fertility is a crucial pathogenic characteristic of PCOS. The primary characteristic of PCOS, androgen excess, is linked to this impairment. It is believed that hyperactivity of the neuroendocrine axis regulating fertility is caused by impaired steroid hormone feedback to GnRH neurons, creating a vicious cycle of excess androgen and reproductive failure. Due to the enormous complexity of researching the human brain, decades of clinical research have failed to identify the mechanisms behind this disability. We have only lately started to understand the function of the brain in the onset and evolution of PCOS, thanks to the creation of preclinical models of the condition. The research presented here shows how crucial the brain is to PCOS ontogeny and pathophysiology and emphasizes the need for a deeper comprehension of the underlying mechanisms.
Article Details

This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Balen AH, Rutherford AJ. Managing anovulatory infertility and polycystic ovary syndrome. Bmj. 2007 Sep 27;335(7621):663-6.
II. Waghmare SV, Shanoo A. Polycystic ovary syndrome: a literature review with a focus on diagnosis, pathophysiology, and management. Cureus. 2023 Oct 20;15(10).
III. Sharma ST, Nieman LK, Feelders RA. Cushing’s syndrome: epidemiology and developments in disease management. Clinical epidemiology. 2015 Apr 17:281-93.
IV. Helvaci N, Yildiz BO. Polycystic ovary syndrome as a metabolic disease. Nature Reviews Endocrinology. 2025 Apr;21(4):230-44.
V. Coutinho EA, Kauffman AS. The role of the brain in the pathogenesis and physiology of polycystic ovary syndrome (PCOS). Medical Sciences. 2019 Aug 2;7(8):84.
VI. The enigma of the gonadotropin-releasing hormone pulse frequency governing individual secretion of luteinizing hormone and follicle-stimulating hormone
VII. Navarro VM. New insights into the control of pulsatile GnRH release: the role of Kiss1/neurokinin B neurons. Frontiers in endocrinology. 2012 Apr 2;3:48.
VIII. Pinto J, Cera N, Pignatelli D. Psychological symptoms and brain activity alterations in women with PCOS and their relation to the reduced quality of life: a narrative review. Journal of endocrinological investigation. 2024 Kim C, Schilder N, Adolphus K, Berry Jul;47(7):1-22.
IX. A, Musillo C, Dye L, Cirulli F, Korosi A, Thuret S. The dynamic influence of nutrition on prolonged cognitive healthspan across the life course: a perspective review. Neuroscience Applied. 2024 Jan 1;3:104072.
X. Abbott DH, Rogers J, Dumesic DA, Levine JE. Naturally occurring and experimentally induced rhesus macaque models for polycystic ovary syndrome: translational gateways to clinical application. Medical Sciences. 2019 Nov 27;7(12):107.
XI. Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M. Polycystic ovary syndrome: etiology, current management, and future therapeutics. Journal of clinical medicine. 2023 Feb 11;12(4):1454.
XII. Constantin S, Bjelobaba I, Stojilkovic SS. Pituitary gonadotroph-specific patterns of gene expression and hormone secretion. Current opinion in pharmacology. 2022 Oct 1;66:102274.
XIII. Solorzano CM, Beller JP, Abshire MY, Collins JS, McCartney CR, Marshall JC. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids. 2012 Mar 10;77(4):332-7.
XIV. Lehman MN. Origins of the ‘KNDy hypothesis’ of GnRH pulse generation. Nature Reviews Endocrinology. 2022 Sep;18(9):521-
XV. Kauffman AS. Androgen inhibition of reproductive neuroendocrine function in females and transgender males. Endocrinology. 2024 Oct;165(10):bqae113.
XVI. McCartney CR, Campbell RE. Abnormal GnRH pulsatility in polycystic ovary syndrome: recent insights. Current opinion in endocrine and metabolic research. 2020 Jun 1;12:78-84.
XVII. McCartney CR, Campbell RE. Abnormal GnRH pulsatility in polycystic ovary syndrome: recent insights. Current opinion in endocrine and metabolic research. 2020 Jun 1;12:78-84.
XVIII. Ruddenklau A, Campbell RE. Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology. 2019 Oct;160(10):2230-42.
XIX. Kauffman AS. Androgen inhibition of reproductive neuroendocrine function in females and transgender males. Endocrinology. 2024 Oct;165(10):bqae113.
XX. Panda SP, Kesharwani A, Singh GD, Prasanth DS, Vatchavai BR, Kumari PK, Panda SK, Mallick SP. Impose of KNDy/GnRH neural circuit in PCOS, ageing, cancer and Alzheimer’s disease: StAR actions in prevention of neuroendocrine dysfunction. Ageing research reviews. 2023 Dec 1;92:102086.
XXI. Emanuel RH, Roberts J, Docherty PD, Lunt H, Campbell RE, Möller K. A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions. Frontiers in endocrinology. 2022 Nov 15;13:1017468.
XXII. Mukherjee P, Roy S, Ghosh D, Nandi SK. Role of animal models in biomedical research: a review. Laboratory animal research. 2022 Jul 1;38(1):18.
XXIII. Ryu Y, Kim SW, Kim YY, Ku SY. Animal models for human polycystic ovary syndrome (PCOS) focused on the use of indirect hormonal perturbations: a review of the literature. International journal of molecular sciences. 2019 Jun 3;20(11):2720.
XXIV. Xue P, Wang Z, Fu X, Wang J, Punchhi G, Wolfe A, Wu S. A hyperandrogenic mouse model to study polycystic ovary syndrome. Journal of visualized experiments: JoVE. 2018 Oct 2(140):58379.
XXV. Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M. Polycystic ovary syndrome: etiology, current management, and future therapeutics. Journal of clinical medicine. 2023 Feb 11;12(4):1454.
XXVI. Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M. Polycystic ovary syndrome: etiology, current management, and future therapeutics. Journal of clinical medicine. 2023 Feb 11;12(4):1454.
XXVII. Hammes SR, Levin ER. Impact of estrogens in males and androgens in females. The Journal of clinical investigation. 2019 May 1;129(5):1818-26.
XXVIII. Hammes SR, Levin ER. Impact of estrogens in males and androgens in females. The Journal of clinical investigation. 2019 May 1;129(5):1818-26.
XXIX. Wolfe A, Wu S. Estrogen receptor-β in the gonadotropin-releasing hormone neuron. InSeminars in reproductive medicine 2012 Jan (Vol. 30, No. 01, pp. 23-31). Thieme Medical Publishers.
XXX. He W, Li X, Adekunbi D, Liu Y, Long H, Wang L, Lyu Q, Kuang Y, O’Byrne KT. Hypothalamic effects of progesterone on regulation of the pulsatile and surge release of luteinising hormone in female rats. Scientific reports. 2017 Aug 14;7(1):8096.
XXXI. Watanabe Y, Fisher L, Campbell RE, Jasoni CL. Defining potential targets of prenatal androgen excess: expression analysis of androgen receptor on hypothalamic neurons in the fetal female mouse brain. Journal of neuroendocrinology. 2023 Jun;35(6):e13302.
XXXII. Moore AM. Impaired steroid hormone feedback in polycystic ovary syndrome: Evidence from preclinical models for abnormalities within central circuits controlling fertility. Clinical endocrinology. 2022 Aug;97(2):199-207.
XXXIII. Ruddenklau A, Campbell RE. Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology. 2019 Oct;160(10):2230-42.
XXXIV. Wang L, Moenter SM. Differential roles of hypothalamic AVPV and arcuate kisspeptin neurons in estradiol feedback regulation of female reproduction. Neuroendocrinology. 2020 Aug 30;110(3-4):172-84.
XXXV. Wang L, Moenter SM. Differential roles of hypothalamic AVPV and arcuate kisspeptin neurons in estradiol feedback regulation of female reproduction. Neuroendocrinology. 2020 Aug 30;110(3-4):172-84.
XXXVI. Ruddenklau A, Campbell RE. Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology. 2019 Oct;160(10):2230-42.
XXXVII. Alesi S, Forslund M, Melin J, Romualdi D, Peña A, Tay CT, Witchel SF, Teede H, Mousa A. Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2023 Sep 1;63.
XXXVIII. Stevenson H, Bartram S, Charalambides MM, Murthy S, Petitt T, Pradeep A, Vineall O, Abaraonye I, Lancaster A, Koysombat K, Patel B. Kisspeptin-neuron control of LH pulsatility and ovulation. Frontiers in Endocrinology. 2022 Nov 21;13:951938.
XXXIX. Stevenson H, Bartram S, Charalambides MM, Murthy S, Petitt T, Pradeep A, Vineall O, Abaraonye I, Lancaster A, Koysombat K, Patel B. Kisspeptin-neuron control of LH pulsatility and ovulation. Frontiers in Endocrinology. 2022 Nov 21;13:951938.
XL. Astapova O, Minor BM, Hammes SR. Physiological and pathological androgen actions in the ovary. Endocrinology. 2019 May;160(5):1166-74.
XLI. Ruddenklau A, Campbell RE. Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology. 2019 Oct;160(10):2230-42.
XLII. Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, Birrell SN. The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer. Nature medicine. 2021 Feb;27(2):310-20.
XLIII. Chukhu M, Dahiya UR, Heemers HV. Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer. Oncogene. 2025 Oct 28;44(41):3883-94.
XLIV. Chukhu M, Dahiya UR, Heemers HV. Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer. Oncogene. 2025 Oct 28;44(41):3883-94.
XLV. Ruddenklau A, Campbell RE. Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology. 2019 Oct;160(10):2230-42.
XLVI. Corrie L, Gulati M, Singh SK, Kapoor B, Khursheed R, Awasthi A, Vishwas S, Chellappan DK, Gupta G, Jha NK, Anand K. Recent updates on animal models for understanding the etiopathogenesis of polycystic ovarian syndrome. Life sciences. 2021 Sep 1;280:119753.
XLVII. Kawwass JF, Sanders KM, Loucks TL, Rohan LC, Berga SL. Increased cerebrospinal fluid levels of GABA, testosterone and estradiol in women with polycystic ovary syndrome. Human Reproduction. 2017 Jul 1;32(7):1450-6.
XLVIII. Ye W, Xie T, Song Y, Zhou L. The role of androgen and its related signals in PCOS. Journal of cellular and molecular medicine. 2021 Feb;25(4):1825-37.
XLIX. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. The Journal of Clinical Endocrinology & Metabolism. 2000 Nov 1;85(11):4047-52.
L. Shabbir S, Khurram E, Moorthi VS, Eissa YT, Kamal MA, Butler AE. The interplay between androgens and the immune response in polycystic ovary syndrome. Journal of translational medicine. 2023 Apr 16;21(1):259.
LI. Lee HR, Jeung EB, Cho MH, Kim TH, Leung PC, Choi KC. Molecular mechanism (s) of endocrine‐disrupting chemicals and their potent oestrogenicity in diverse cells and tissues that express oestrogen receptors. Journal of cellular and molecular medicine. 2013 Jan;17(1):1-1.
LII. Senapati D, Sharma V, Rath SK, Rai U, Panigrahi N. Functional implications and therapeutic targeting of androgen response elements in prostate cancer. Biochimie. 2023 Nov 1;214:188-98.